• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Urinary Tract Cancer - Pipeline Review, H2 2012 Product Image

Urinary Tract Cancer - Pipeline Review, H2 2012

  • ID: 2216802
  • July 2012
  • 665 pages
  • Global Markets Direct

Urinary Tract Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Urinary Tract Cancer - Pipeline Review, H2 2012', provides an overview of the Urinary Tract Cancer therapeutic pipeline. This report provides information on the therapeutic development for Urinary Tract Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Tract Cancer. 'Urinary Tract Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Urinary Tract Cancer.
- A review of the Urinary Tract Cancer products under development by companies and READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 11
List of Figures 14
Introduction 15
REPORT COVERAGE 15
Urinary Tract Cancer Overview 16
Therapeutics Development 17
An Overview of Pipeline Products for Urinary Tract Cancer 17
Urinary Tract Cancer Therapeutics under Development by Companies 19
Urinary Tract Cancer Therapeutics under Investigation by Universities/Institutes 25
Late Stage Products 34
Comparative Analysis 34
Mid Clinical Stage Products 35
Comparative Analysis 35
Early Clinical Stage Products 36
Comparative Analysis 36
Discovery and Pre-Clinical Stage Products 37
Comparative Analysis 37
Urinary Tract Cancer Therapeutics – Products under Development by Companies 38
Urinary Tract Cancer Therapeutics – Products under Investigation by Universities/Institutes 44
Companies Involved in Urinary Tract Cancer Therapeutics Development 58
Bristol-Myers Squibb Company 58
Boehringer Ingelheim GmbH 59
Kyowa Hakko Kirin Co., Ltd. 60
Abbott Laboratories 61
Amgen Inc. 62
AstraZeneca PLC 63
Eli Lilly and Company 64
GlaxoSmithKline plc 65
Seattle Genetics, Inc. 66
Genentech, Inc. 67
Inovio Biomedical Corporation 68
Oxford BioMedica plc 69
Celltrion, Inc. 70
Novartis AG 71
ImClone Systems Incorporated 72
Astellas Pharma Inc. 73
Ono Pharmaceutical Co., Ltd. 74
OSI Pharmaceuticals, Inc. 75
Pfizer Inc. 76
Taiho Pharmaceutical Co., Ltd. 77
Exelixis, Inc. 78
Bayer AG 79
MannKind Corporation 80
3SBio Inc. 81
Hemispherx Biopharma, Inc. 82
Celldex Therapeutics, Inc. 83
Active Biotech AB 84
AEterna Zentaris Inc. 85
Jennerex Biotherapeutics, Inc. 109
Endocyte, Inc. 110
Advenchen Laboratories, LLC 111
Immutep S.A. 112
Vaccinogen, Inc. 113
Tigris Pharmaceuticals, Inc. 114
Viventia Biotechnologies Inc. 115
TRACON Pharmaceuticals, Inc. 116
Pierre Fabre Medicament 117
n.v. BRUCELLS s.a. 118
Medical Enzymes AG 119
Urinary Tract Cancer – Therapeutics Assessment 120
Assessment by Monotherapy Products 120
Assessment by Combination Products 121
Assessment by Route of Administration 122
Assessment by Molecule Type 124
Drug Profiles 127
AEZS-108 - Drug Profile 127
Perifosine - Drug Profile 129
BMS-582664 - Drug Profile 132
Volasertib - Drug Profile 134
AMG 102 - Drug Profile 136
Regorafenib - Drug Profile 137
Inlyta - Drug Profile 139
Sutent - Drug Profile 141
RG7422 - Drug Profile 143
Darleukin - Drug Profile 145
Recentin - Drug Profile 146
ABT-869 - Drug Profile 148
OSI-930 - Drug Profile 150
OSI-027 - Drug Profile 151
MDX-1203 - Drug Profile 152
CDX-1127 - Drug Profile 153
Foretinib - Drug Profile 154
SGN-75 - Drug Profile 156
ANYARA - Drug Profile 157
LOR-1284 - Drug Profile 158
LOR-2040 - Drug Profile 159
MKC1106-PP - Drug Profile 160
IL-2 XL - Drug Profile 162
IMA901 - Drug Profile 163
CA-9 - Drug Profile 164
TroVax - Drug Profile 165
Cabozantinib - Drug Profile 167
NuLeusin - Drug Profile 169
JX-594 - Drug Profile 170
CDX-014 - Drug Profile 171
Curaxin CBLC102 - Drug Profile 172
CXCR4 Antibody - Drug Profile 175
Archexin - Drug Profile 176
AGS-003 - Drug Profile 178
Vargatef - Drug Profile 180
Eoquin - Drug Profile 182
Eoquin - Drug Profile 184
CYT107 - Drug Profile 186
GlutaDON - Drug Profile 188
Folotyn - Drug Profile 190
Trabedersen - Drug Profile 193
OncoVAX - Drug Profile 195
Tivozanib - Drug Profile 197
Vicinium - Drug Profile 199
CG0070 - Drug Profile 201
BAY 43-9006 - Drug Profile 203
Piritrexim - Drug Profile 204
5-Fluorouracil - Drug Profile 205
Camptosar - Drug Profile 206
GFB-204 - Drug Profile 207
C6776 - Drug Profile 208
Rencarex - Drug Profile 209
R935788 - Drug Profile 211
EC17 - Drug Profile 212
Hemoximer - Drug Profile 213
TKI258 - Drug Profile 215
TKI258 - Drug Profile 217
BNC105 - Drug Profile 219
ProtoCure Intravesical Instillation Solution - Drug Profile 220
Oxaliplatin - Drug Profile 222
ATN-658 - Drug Profile 223
S-1 + Sorafenib - Drug Profile 224
BEZ235 - Drug Profile 225
ImmuFact IMP321 - Drug Profile 227
ZD6474 - Drug Profile 228
DMS612 - Drug Profile 230
Yttrium-90 Conjugated Chimeric G250 - Drug Profile 231
Recombinant Human IL-15 - Drug Profile 232
Fluorouracil + Suramin - Drug Profile 233
Velcade + Avastin - Drug Profile 235
Temsirolimus for Renal Cancer - Drug Profile 236
CC-5013 - Drug Profile 237
Bevacizumab + Aldesleukin - Drug Profile 238
5-Azacitidine + Bevacizumab - Drug Profile 239
Abraxane - Drug Profile 241
Tarceva - Drug Profile 243
RAD001 + Sunitinib - Drug Profile 245
BAY 43-9006 + Gemcitabine + Capecitabine - Drug Profile 246
PEG-Intron + Nexavar - Drug Profile 248
Sorafenib + RAD001 - Drug Profile 249
LBH589 + Nexavar - Drug Profile 250
Lutetium-177 Labeled cG250 - Drug Profile 251
Everolimus - Drug Profile 252
Everolimus - Drug Profile 253
Docetaxel + Zactima - Drug Profile 254
Cisplatin + Gemcitabine + Bevacizumab - Drug Profile 255
Vorinostat - Drug Profile 257
Gemcitabine + Capecitabine - Drug Profile 259
Liposomal Vincristine - Drug Profile 260
Fluorouracil + Leucovorin + Gemcitabine + Cisplatin - Drug Profile 261
Tarceva + Avastin - Drug Profile 373
Filgrastim + Carboplatin + Gemcitabine + Ifosfamide + Paclitaxel - Drug Profile 435
Tumor Lysate Pulsed Dendritic Cell Vaccine + Stem Cell Transplantation - Drug Profile 437
Survivin + Telomerase Peptide + Dendritic Cells + Zadaxin + Interleukin-2 - Drug Profile 438
177Lu-DOTA-cG250 - Drug Profile 440
177Lu-DOTA-cG250 - Drug Profile 441
Autologous Tumor Lysate-Dendritic Cell Vaccine + Bevacizumab + Interleukin-2 + Interferon Alfa - Drug Profile 443
Gemcitabine + Cisplatin + Lenalidomide - Drug Profile 445
Methotrexate + Vinblastine + Cisplatin - Drug Profile 447
GW786034 - Drug Profile 479
Genistein + Interleukin-2 - Drug Profile 480
Everolimus + Paclitaxel - Drug Profile 481
Gemcitabine + Cisplatin + Carboplatin - Drug Profile 482
Gemcitabine + Paclitaxel + Doxorubicin + Pegfilgrastim - Drug Profile 483
Gemcitabine + Cisplatin - Drug Profile 485
Pazopanib Hydrochloride - Drug Profile 487
Sunitinib - Drug Profile 488
Pazopanib + Bevacizumab - Drug Profile 489
Votrient + Afinitor - Drug Profile 490
RAD001 + Lenalidomide - Drug Profile 491
Cisplatin + Gemcitabine + Sorafenib - Drug Profile 492
Pazopanib - Drug Profile 494
Gemcitabine - Drug Profile 495
Cisplatin + Cyclophosphamide+ Doxorubicin - Drug Profile 496
Methotrexate - Drug Profile 498
Thiotepa - Drug Profile 499
Sirolimus + Celecoxib + Etoposide + Cyclophosphamide - Drug Profile 500
RO4929097 + Dexamethasone - Drug Profile 501
ALT-803 - Drug Profile 502
Tyverb - Drug Profile 504
Gemcitabine Hydrochloride + Doxorubicin + Paclitaxel + Cisplatin + Filgrastim - Drug Profile 505
Doxorubicin + Gemcitabine + Paclitaxel + Cisplatin + Ifosfamide + Filgrastim - Drug Profile 507
MGA271 - Drug Profile 509
DN24-02 - Drug Profile 537
Sunitinib + Bevacizumab - Drug Profile 538
Debio 1141 - Drug Profile 540
Sunitinib + Gefitinib - Drug Profile 541
LY2510924 + Sunitinib - Drug Profile 542
Gemcitabine + Cisplatin + Panitumumab - Drug Profile 543
Dendritic Cell Activated Cytokine-Induced Killer Cell - Drug Profile 545
Interleukin-2 + Interferon Alfa-2b + Bevacizumab - Drug Profile 546
HLA-A02 Restricted HIG2 - Drug Profile 547
B7/IL-7-Transfected Allogeneic Tumor Cell Vaccine - Drug Profile 548
Sorafenib + Gemcitabine + Capecitabine - Drug Profile 549
CHP-NY-ESO-1 Cancer Vaccine + MIS416 - Drug Profile 551
Pazopanib + Everolimus - Drug Profile 552
AL8326 - Drug Profile 553
CEL-031 - Drug Profile 554
AMG 172 - Drug Profile 556
ACE-041 + sunitinib - Drug Profile 557
Javlor + Carboplatin - Drug Profile 558
V934 - Drug Profile 560
Urinary Tract Cancer Therapeutics – Drug Profile Updates 562
Urinary Tract Cancer Therapeutics – Discontinued Products 613
Urinary Tract Cancer Therapeutics - Dormant Products 615
Urinary Tract Cancer – Product Development Milestones 632
Featured News & Press Releases 632
Appendix 642
Methodology 642
Coverage 642
Secondary Research 642
Primary Research 642
Expert Panel Validation 642
Contact Us 643
Disclaimer 643

List of Tables
Number of Products Under Development for Urinary Tract Cancer, H2 2012 39
Products under Development for Urinary Tract Cancer – Comparative Analysis, H2 2012 40
Number of Products under Development by Companies, H2 2012 42
Number of Products under Development by Companies, H2 2012 (Contd..1) 43
Number of Products under Development by Companies, H2 2012 (Contd..2) 44
Number of Products under Development by Companies, H2 2012 (Contd..3) 45
Number of Products under Development by Companies, H2 2012 (Contd..4) 46
Number of Products under Investigation by Universities/Institutes, H2 2012 48
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 49
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 50
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 51
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 52
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 53
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 54
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 55
Comparative Analysis by Late Stage Development, H2 2012 56
Comparative Analysis by Mid Clinical Stage Development, H2 2012 57
Comparative Analysis by Early Clinical Stage Development, H2 2012 58
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 59
Products under Development by Companies, H2 2012 60
Products under Development by Companies, H2 2012 (Contd..1) 61
Products under Development by Companies, H2 2012 (Contd..2) 62
Products under Development by Companies, H2 2012 (Contd..3) 63
Products under Development by Companies, H2 2012 (Contd..4) 64
Products under Development by Companies, H2 2012 (Contd..5) 65
Products under Investigation by Universities/Institutes, H2 2012 66
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 67
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 68
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 69
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 70
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 71
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 72
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 73
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 74
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 75
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 76
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 77
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 78
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 79
Bristol-Myers Squibb Company, H2 2012 80
Boehringer Ingelheim GmbH, H2 2012 81
Kyowa Hakko Kirin Co., Ltd., H2 2012 82
Abbott Laboratories, H2 2012 83
Amgen Inc., H2 2012 84
AstraZeneca PLC, H2 2012 85
Eli Lilly and Company, H2 2012 86
GlaxoSmithKline plc, H2 2012 87
Seattle Genetics, Inc., H2 2012 88
Genentech, Inc., H2 2012 89
Inovio Biomedical Corporation, H2 2012 90
Oxford BioMedica plc, H2 2012 91
Celltrion, Inc., H2 2012 92
Novartis AG, H2 2012 93
ImClone Systems Incorporated, H2 2012 94
Astellas Pharma Inc., H2 2012 95
Ono Pharmaceutical Co., Ltd., H2 2012 96
OSI Pharmaceuticals, Inc., H2 2012 97
Pfizer Inc., H2 2012 98
Taiho Pharmaceutical Co., Ltd., H2 2012 99
Exelixis, Inc., H2 2012 100
Bayer AG, H2 2012 101
MannKind Corporation, H2 2012 102
3SBio Inc., H2 2012 103
Hemispherx Biopharma, Inc., H2 2012 104
Celldex Therapeutics, Inc., H2 2012 105
Active Biotech AB, H2 2012 106
AEterna Zentaris Inc., H2 2012 107
Lorus Therapeutics Inc, H2 2012 108
Bionomics Limited, H2 2012 109
Northwest Biotherapeutics, Inc., H2 2012 110
Cleveland BioLabs, Inc., H2 2012 111
Allos Therapeutics, Inc, H2 2012 112
Flamel Technologies S.A., H2 2012 113
Dendreon Corporation, H2 2012 114
MOLOGEN AG, H2 2012 115
OncoTherapy Science, Inc., H2 2012 116
Threshold Pharmaceuticals, Inc., H2 2012 117
Rexahn Pharmaceuticals, Inc., H2 2012 118
Spectrum Pharmaceuticals, Inc., H2 2012 119
Debiopharm Group, H2 2012 120
Antisense Pharma GmbH, H2 2012 121
Wilex AG, H2 2012 122
Philogen S.p.A., H2 2012 123
Acceleron Pharma, Inc., H2 2012 124
immatics biotechnologies GmbH, H2 2012 125
Curacyte AG, H2 2012 126
Argos Therapeutics, Inc., H2 2012 127
Cytheris SA, H2 2012 128
Altor BioScience Corporation, H2 2012 129
MacroGenics, Inc., H2 2012 130
Jennerex Biotherapeutics, Inc., H2 2012 131
Endocyte, Inc., H2 2012 132
Advenchen Laboratories, LLC, H2 2012 133
Immutep S.A., H2 2012 134
Vaccinogen, Inc., H2 2012 135
Tigris Pharmaceuticals, Inc., H2 2012 136
Viventia Biotechnologies Inc., H2 2012 137
TRACON Pharmaceuticals, Inc., H2 2012 138
Pierre Fabre Medicament, H2 2012 139
n.v. BRUCELLS s.a., H2 2012 140
Medical Enzymes AG, H2 2012 141
Assessment by Monotherapy Products, H2 2012 142
Assessment by Combination Products, H2 2012 143
Assessment by Stage and Route of Administration, H2 2012 145
Assessment by Stage and Molecule Type, H2 2012 148
Urinary Tract Cancer Therapeutics – Drug Profile Updates 584
Urinary Tract Cancer Therapeutics – Discontinued Products 635
Urinary Tract Cancer Therapeutics – Discontinued Products (Contd..1) 636
Urinary Tract Cancer Therapeutics – Dormant Products 637
Urinary Tract Cancer Therapeutics – Dormant Products (Contd..1) 638
Urinary Tract Cancer Therapeutics – Dormant Products (Contd..2) 639
Urinary Tract Cancer Therapeutics – Dormant Products (Contd..3) 640
Urinary Tract Cancer Therapeutics – Dormant Products (Contd..4) 641
Urinary Tract Cancer Therapeutics – Dormant Products (Contd..5) 642
Urinary Tract Cancer Therapeutics – Dormant Products (Contd..6) 643
Urinary Tract Cancer Therapeutics – Dormant Products (Contd..7) 644
Urinary Tract Cancer Therapeutics – Dormant Products (Contd..8) 645
Urinary Tract Cancer Therapeutics – Dormant Products (Contd..9) 646
Urinary Tract Cancer Therapeutics – Dormant Products (Contd..10) 647
Urinary Tract Cancer Therapeutics – Dormant Products (Contd..11) 648
Urinary Tract Cancer Therapeutics – Dormant Products (Contd..12) 649
Urinary Tract Cancer Therapeutics – Dormant Products (Contd..13) 650
Urinary Tract Cancer Therapeutics – Dormant Products (Contd..14) 651
Urinary Tract Cancer Therapeutics – Dormant Products (Contd..15) 652
Urinary Tract Cancer Therapeutics – Dormant Products (Contd..16) 653

List of Figures
Number of Products under Development for Urinary Tract Cancer, H2 2012 39
Products under Development for Urinary Tract Cancer – Comparative Analysis, H2 2012 40
Products under Development by Companies, H2 2012 41
Products under Investigation by Universities/Institutes, H2 2012 47
Late Stage Products, H2 2012 56
Mid Clinical Stage Products, H2 2012 57
Early Clinical Stage Products, H2 2012 58
Discovery and Pre-Clinical Stage Products, H2 2012 59
Assessment by Monotherapy Products, H2 2012 142
Assessment by Combination Products, H2 2012 143
Assessment by Route of Administration, H2 2012 144
Assessment by Stage and Route of Administration, H2 2012 145
Assessment by Molecule Type, H2 2012 146
Assessment by Stage and Molecule Type, H2 2012 147

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos